- Accueil >
- Publications >
- Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response
Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response
Auteurs
Sarah Boughdad, Laurence Champion, Veronique Becette, Pascal Cherel, Emmanuelle Fourme, Jerome Lemonnier, Florence Lerebours, Jean-Louis Alberini
Résumé
Abstract
Background
Neoadjuvant endocrine therapy (NET) has shown efficacy in terms of clinical response and surgical outcome in postmenopausal patients with estrogen receptor-positive / HER2-negative breast cancer (ER+/HER2- BC) but monitoring of tumor response is challenging. The aim of the present study was to investigate the value of an early metabolic response compared to morphological and pathological responses in this population.
Methods
This was an ancillary study of CARMINA 02, a phase II clinical trial evaluating side-by-side the efficacy of 4 to 6 months of anastrozole or fulvestrant. Positron Emission Tomography/Computed Tomography using 2-deoxy-2-[
Results
Tumor size measured on US and on MRI was smaller in mR than mNR, with the highest statistically significant difference at M1 (
Conclusions
FDG-PET/CT imaging could become a “surrogate marker” to monitor tumor response, especially as NET is a valuable treatment option in postmenopausal women with ER+/HER2- BC.